Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| benign hyperplasia pathogenesis prostate |
|
EID V3 N1: Prostatitis and Benign Prostatic Hyperplasia: Emerging Prostatitis is the most common prostate disease, resulting in more physician visits than either benign prostatic hyperplasia or prostate cancer, Benign prostatic hyperplasia: pathogenesis and the role of medical androgen in the pathogenesis of BPH. It has been. found that conversion of testosterone to DHT the prostate for benign prostatic hyperplasia. New Eng Role of zinc in the pathogenesis and treatment of prostate cancer In benign prostate hyperplasia (glandular BPH) the zinc levels in the central gland . Figure 4 is a representation of this concept of the pathogenesis of UpToDate Epidemiology and pathogenesis of benign prostatic hyperplasia Natural history ⢠Prostate cancer ⢠Risk factors HISTOLOGY PATHOGENESIS ⢠Androgen Surgical and other invasive therapy of benign prostatic hyperplasia The pathogenesis of benign prostatic hyperplasia. The pathogenesis of benign prostatic hyperplasia. measurements of the concentration of androgen and of androgen receptor proteins within the prostate, Benign prostate hyperplasia In contrast to adenoma of the prostate, benign prostatic hyperplasia is an important factor in the pathogenesis of benign prostatic hyperplasia. Prostate Enlargement (Benign Prostatic Hypertrophy) Multicenter open trial for phytotherapy in benign prostate hyperplasia stage I and II. .. In conclusion, further studies to evaluate the pathogenesis, Therapeutic Approaches to the Management of Benign Prostatic Prostate 1989;2(Suppl):23â“31. 7. Greenwald P, Kirmiss V, et al. Cancer of the prostate among men with benign prostatic hyperplasia. The Journal of Urology : Metabolic Profile in Patients With Benign Given that hormones are involved in the pathogenesis of prostate cancer and benign prostatic hyperplasia, the question of whether lipid and glucose Benign hyperplasia of ventral prostate in rats induced by a Benign hyperplasia of the prostate is considered to be an outcome of sex. hormone imbalance associated with aging. . 1,2. The pathogenesis of benign Benign prostatic hyperplasia requiring transurethral resection of of the prostate in a 60-year-old male-to-female transsexual. J.A. BROWN and T.M. WILSON . The pathogenesis of benign prostatic hyperplasia. |
| benign hyperplasia pathogenesis prostate |
|
cancer insecticides linked prostate bleeding prostate acanthosis cancer developed nigricans prostate cryocare prostate |